These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 7962370)

  • 1. Pattern of gonadotrophin secretion in patients with hyperandrogenaemic amenorrhoea before and after ovarian wedge resection.
    Graf MA; Bielfeld P; Graf C; Distler W
    Hum Reprod; 1994 Jun; 9(6):1022-6. PubMed ID: 7962370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of chronic hyperandrogenism and/or administered central nervous system insulin on ovarian manifestation and gonadotropin and steroid secretion.
    Allon MA; Leach RE; Dunbar J; Diamond MP
    Fertil Steril; 2005 Apr; 83 Suppl 1():1319-26. PubMed ID: 15831308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.
    Blank SK; McCartney CR; Helm KD; Marshall JC
    Semin Reprod Med; 2007 Sep; 25(5):352-9. PubMed ID: 17710731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
    McCartney CR; Eagleson CA; Marshall JC
    Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of flutamide on pulsatile gonadotrophin secretion in hyperandrogenaemic women.
    Sir-Petermann T; Rabenbauer B; Wildt L
    Hum Reprod; 1993 Nov; 8(11):1807-12. PubMed ID: 8288741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
    Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome.
    Poretsky L; Piper B
    Obstet Gynecol; 1994 Oct; 84(4):613-21. PubMed ID: 8090402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced frequency of luteinizing hormone pulses in women with weight loss-related amenorrhoea and multifollicular ovaries.
    Mason HD; Sagle M; Polson DW; Kiddy D; Dobriansky D; Adams J; Franks S
    Clin Endocrinol (Oxf); 1988 Jun; 28(6):611-8. PubMed ID: 3151067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Do androgens modulate luteinizing hormone secretion in women?].
    Sir T
    Rev Med Chil; 1997 Jun; 125(6):710-8. PubMed ID: 9515293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin modulation of luteinizing hormone secretion in normal female volunteers and lean polycystic ovary syndrome patients.
    Moret M; Stettler R; Rodieux F; Gaillard RC; Waeber G; Wirthner D; Giusti V; Tappy L; Pralong FP
    Neuroendocrinology; 2009; 89(2):131-9. PubMed ID: 18832802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone pulsatile release and the length of lactational amenorrhoea.
    Díaz S; Cárdenas H; Zepeda A; Brandeis A; Schiappacasse V; Miranda P; Serón-Ferré M; Croxatto HB
    Hum Reprod; 1995 Aug; 10(8):1957-61. PubMed ID: 8567822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gonadotropins in amenorrhea].
    van der Merwe JV
    S Afr Med J; 1981 Feb; 59(8):255-7. PubMed ID: 6781076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypergonadotropic amenorrhea and premature ovarian failure: a review.
    Rebar RW
    J Reprod Med; 1982 Apr; 27(4):179-86. PubMed ID: 6808131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone administration modulates the neuroendocrine control of luteinizing hormone secretion in hypothalamic amenorrhoea.
    Genazzani AD; Gastaldi M; Petraglia F; Battaglia C; Surico N; Volpe A; Genazzani AR
    Hum Reprod; 1995 Nov; 10(11):2868-71. PubMed ID: 8747034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypergonadotrophic amenorrhoea.
    Van Der Merwe JV
    S Afr Med J; 1981 Jan; 59(2):42-6. PubMed ID: 6779383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.